Cytokinetics (CYTK) Misses Q3 EPS by 98c
Tweet
Share
E-mail
Get Alerts CYTK Hot Sheet
Join SI Premium – FREE
Cytokinetics (NASDAQ: CYTK) reported Q3 EPS of ($2.55), $0.98 worse than the analyst estimate of ($1.57). Revenue for the quarter came in at $1.93 million versus the consensus estimate of $6.05 million.
For earnings history and earnings-related data on Cytokinetics (CYTK) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- BofA maintains underperform ratings on six BDC stocks
- Boeing names Ryan Shedd as new SVP and controller
- Jefferies sees metals breakout on currency concerns
Create E-mail Alert Related Categories
EarningsRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
